Synthesis and biological studies of a new series of 5- heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1720-1729

  Pastorin, Giorgia ^a   Da Ros, Tatiana ^a   Bolcato, Chiara ^a   Montopoli, Christian ^c   Moro, Stefano ^c   Cacciari, Barbara ^b   Baraldi, Pier Giovanni ^b   Varani, Katia ^b   Borea, Pier Andrea ^b   Spalluto, Giampiero ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; CARBAMOYLAMINOPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDINE DERIVATIVE; HETEROCYCLIC COMPOUND; PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVE; PYRIDINE DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; LIGAND BINDING; MOLECULAR MODEL; SOLUBILITY;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE; CHO CELLS; CRICETINAE; HUMANS; MODELS, MOLECULAR; PYRAZOLES; PYRIMIDINES; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 33644858876     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051147+     Document Type: Article

References (43)

1. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552.
2. Jacobson, K. A.; Knutsen, L. J. S. P1 and P2 purine and pyrimidine receptor ligands. In Handbook of Experimental Pharmacology; Springer: Berlin, 2001, Vol. 151/1 (purinergic and pyrimidinergic Signalling I), pp 129-175.
3. Jacobson, K. A.; Suzuki, F. Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors. Drug. Dev. Res. 1996, 39, 289-300.
4. Meyerhof, W.; Muller-Brechlin, R.; Richter, D. Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett. 1991, 284, 155-160.
5. 3 adenosine receptor. Biochim. Biophys. Acta 1993, 1179, 105-107.
6. 3 adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10365-10369.
7. 3 receptors: Pharmacological properties, species differences and receptor functions. Trends Pharmacol. Sci. 1994, 15, 298-306.
8. 3 adenosine receptor gene, adora3. Genomics 1995, 30, 118-119.
9. 3 receptors. J. Pharmacol. Exp. Ther. 1997, 280, 122-128.
10. 3 receptor in rat brain. Mol. Pharmacol. 1995, 48, 1038-1045.
11. 2+-ionophore-induced secretion in a rat mast-cell line. J. Pharmacol. Exp. Ther. 1996, 276, 837-845.
12. Rorke, S.; Holgate, S. T. Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Med. 2002, 1, 99-105.
13. Merighi, S.; Mirandola, P.; Varani, K.; Gessi, S.; Leung, E.; Baraldi, P. G.; Tabrizi, M. A.; Borea, P. A. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol. Ther. 2003, 100, 31-48.
14. 3 adenosine receptor effects cell cycle progression and cell growth. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 225-234.
15. 3 Adenosine receptor ligands; history and perspectives. Med. Res. Rev. 2000, 20, 103-128.
16. Moro, S.; Deflorian, F.; Spalluto, G.; Pastorin, G.; Cacciari, B. et al. Demystifying the three-dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chem. Commun. (Camb) 2003, 2949-2956.
17. 3 adenosine receptors. In Annual Reports in Medicinal Chemistry, 1st ed.; Doherty, A. M., Ed.; Elsevier: New York, 2003: pp 121-130.
18. 3 adenosine receptor antagonists. J. Med. Chem. 1999, 42, 4473-4478.
19. 8 pyrazole nitrogen. J. Med. Chem. 2000, 43, 4768-4780.
20. 3 Adenosine Receptor Antagonists. J. Med. Chem. 2002, 45, 770-780.
21. 2B adenosine receptor subtypes: a molecular modeling investigation. J. Med. Chem. 2003, 46, 4287-96.
22. 3 adenosine receptor antagonist, J. Med. Chem. 2002, 45, 3579-3582.
23. Saikachi, H.; Kitagawa, T.; Nasu, A.; Sasaki, H. Synthesis of Furan Derivatives LXXXVII. Chem. Pharm. Bull. 1981, 29, 237-244.
24. Curtius, T.; Mohr, E. Ueberführung von nicotinsaure in γ amidopyridin. Ber. 1898, 31, 2493-2495.
25. 2 adenosine receptor antagonists, antagonists. Eur. J. Med. Chem. 1993, 28, 569-577.
26. Schmidt, P.; Eichenberger, K.; Wilhelm, M.; Druey, J. Pyrazolopyrimidine III. Helv. Chim. Acta 1959, 39, 349-359.
27. Todd, D. The Wolff-Kishner reduction. J. Am. Chem. Soc. 1949, 71, 1353-1355.
28. 1 adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1987, 336, 204-210.
29. 3 adenosine receptors. Mol. Pharmacol. 2000, 57, 968-975.
30. 3 adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 359, 7-10.
31. Hansch, C.; Leo, A.; Taft, R. W. A survey of Hammett substituent. Constants and resonance and field parameters. Chem. Rev. 1991, 91, 165-195.
32. 3 adenosine receptor as an example. Trends Pharmacol. Sci. 2005, 26, 44-51.
33. 3 Adenosine Receptor Antagonists: Pyrazolo[4,3-e]1,2,4-Triazolo[1,5-c]Pyrimidine Derivatives as a Key Study. J. Med. Chem. 2005, 48, 152-162.
34. 3 adenosine receptor. J. Biol. Chem. 2002, 277, 19056-19063.
35. Klotz, K. N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes- characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 357, 1-9.
36. Bradford, M. M. A rapid sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding. Anal. Biochem. 1976, 72, 248-254.
37. OpenMosix: http://www.openMosix.org, 2004.
38. Molecular Operating Environment (MOE 2004.03), C. C. G., Inc, 1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3 × 3.
39. MOPAC available from Quantum Chemistry Program Exchange., ver.6.0.
40. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H. et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
41. Cornell, W. D. C., P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5196.
42. Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead, D. R.; Eldridge, M. D. Flexible Docking Using Tabu Search and an Empirical Estimate of Binding Affinity. Proteins: Struct., Funct. Genet. 1998, 33, 367-382.
43. Halgren, T. Merck Molecular Force Field. I. Basis. Form, Scope, Parameterization, and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.